Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016
Published Jun 30, 2016
120 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016, provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy

  
Source:
Document ID
GMDHC0228TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview101
Therapeutics Development114
  Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Stage of Development111
  Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Therapy Area121
  Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Indication132
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Companies174
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Universities/Institutes212
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Therapeutics Assessment237
  Assessment by Monotherapy/Combination Products231
  Assessment by Mechanism of Action242
  Assessment by Route of Administration262
  Assessment by Molecule Type282
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Companies Involved in Therapeutics Development3020
  Amgen Inc.301
  Antisense Therapeutics Limited311
  Astellas Pharma Inc.321
  AstraZeneca Plc331
  Axelar AB341
  Boehringer Ingelheim GmbH351
  Bristol-Myers Squibb Company361
  Eli Lilly and Company371
  F. Hoffmann-La Roche Ltd.381
  Genmab A/S391
  Immunomedics, Inc.401
  Insmed Incorporated411
  Merck &Co., Inc.421
  Merrimack Pharmaceuticals, Inc.431
  Novartis AG441
  PharmAbcine, Inc.451
  ProteoThera, Inc.461
  Silver Creek Pharmaceuticals, Inc.471
  Sucampo Pharmaceuticals, Inc.481
  TyrNovo Ltd.491
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Drug Profiles5046
  1R-15-15 Drug Profile501
  1R-3s Drug Profile511
  1R-E1-E1 Drug Profile521
  ATL-1101 Drug Profile532
  AXL-1717 Drug Profile553
  AZD-3463 Drug Profile581
  BI-893923 Drug Profile591
  BMS-754807 Drug Profile601
  CT-707 Drug Profile611
  dalotuzumab Drug Profile622
  Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis Drug Profile641
  ganitumab Drug Profile653
  lenaldekar Drug Profile681
  linsitinib Drug Profile693
  M-590 Drug Profile721
  mecasermin rinfabate (recombinant) Drug Profile733
  MM-141 Drug Profile762
  Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology Drug Profile781
  Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders Drug Profile791
  NT-219 Drug Profile801
  Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine Drug Profile811
  Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis Drug Profile821
  Recombinant Protein to Agonize Insulin Like Growth Factor 1 Receptor for Phelan-McDermid Syndrome Drug Profile831
  Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer Drug Profile841
  Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction Drug Profile851
  RU-105 Drug Profile861
  Small Molecule to Antagonize IGF-1R for Oncology Drug Profile871
  Small Molecules to Inhibit IGF-1R for Oncology Drug Profile881
  Small Molecules to Inhibit IGF-1R/IR for Oncology Drug Profile891
  teprotumumab Drug Profile902
  Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer Drug Profile921
  vesiculin Drug Profile931
  XGFR-2 Drug Profile941
  XGFR-4 Drug Profile951
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Dormant Projects967
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Discontinued Products1035
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Featured News &Press Releases10811
  Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave s Orbitopathy1081
  May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer1081
  Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients1091
  Mar 17, 2015: Study suggests precision medicine for adrenal cancer1101
  Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium1111
  Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer1121
  Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting1131
  Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics1131
  Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer1141
  Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer1151
  Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics1161
  Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease1161
  Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy1161
  Apr 02, 2013: Axelar Announces Preliminary Results From Phase II Study Demonstrating Efficacy Of AXL1717 In Non-Small Cell Lung Cancer Patients1171
  Jan 21, 2013: Axelar Initiates Phase I/II Study Of AXL1717 In Patients With Malignant Astrocytomas In US1172
Appendix1192
  Methodology1191
  Coverage1191
  Secondary Research1191
  Primary Research1191
  Expert Panel Validation1191
  Contact Us1191
  Disclaimer1201

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Insulin-Like-Growth-Factor-1-Receptor-CD221-or-IGF1R-or-EC-2-7-10-1-Pipeline-Review-H1-2016-2088-16114>
  
APA:
Global Markets Direct - Market Research. (2016). Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Insulin-Like-Growth-Factor-1-Receptor-CD221-or-IGF1R-or-EC-2-7-10-1-Pipeline-Review-H1-2016-2088-16114>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.